Benralizumab

Benralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]

Benralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD125
Clinical data
Trade namesFasenra
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10060N1724O2028S42
Molar mass146.0 kg/mol g·mol−1
 NY (what is this?)  (verify)

Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3][4] It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma.[5] It was also granted orphan drug designation by the FDA for treatment of eosinophilic oesophagitis in August 2019.[6]

References
  1. Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
  2. Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs: the investigational drugs journal. 13 (9): 601–604. PMID 20799138.
  3. AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
  4. Nair, Parameswaran; Wenzel, Sally; Rabe, Klaus F.; Bourdin, Arnaud; Lugogo, Njira L.; Kuna, Piotr; Barker, Peter; Sproule, Stephanie; Ponnarambil, Sandhia; Goldman, Mitchell (2017). "Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma". New England Journal of Medicine. 376 (25): 2448. doi:10.1056/NEJMoa1703501. PMID 28530840.
  5. "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.
  6. "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". www.astrazeneca.com. Retrieved 2019-10-29.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.